ATE432711T1 - Arginindeiminase enthaltende erythrozyten - Google Patents

Arginindeiminase enthaltende erythrozyten

Info

Publication number
ATE432711T1
ATE432711T1 AT06744562T AT06744562T ATE432711T1 AT E432711 T1 ATE432711 T1 AT E432711T1 AT 06744562 T AT06744562 T AT 06744562T AT 06744562 T AT06744562 T AT 06744562T AT E432711 T1 ATE432711 T1 AT E432711T1
Authority
AT
Austria
Prior art keywords
indeiminase
argine
erythrocytes containing
erythrocytes
arginine deiminase
Prior art date
Application number
AT06744562T
Other languages
English (en)
Inventor
Yann Godfrin
Pierre-Olivier Goineau
Original Assignee
Erytech Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erytech Pharma filed Critical Erytech Pharma
Application granted granted Critical
Publication of ATE432711T1 publication Critical patent/ATE432711T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03006—Arginine deiminase (3.5.3.6)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06744562T 2005-04-25 2006-04-25 Arginindeiminase enthaltende erythrozyten ATE432711T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0504122A FR2884717B1 (fr) 2005-04-25 2005-04-25 Erythrocytes renfermant de l'arginine deiminase
PCT/IB2006/001004 WO2006114691A1 (en) 2005-04-25 2006-04-25 Erythrocytes containing arginine deiminase

Publications (1)

Publication Number Publication Date
ATE432711T1 true ATE432711T1 (de) 2009-06-15

Family

ID=35787979

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06744562T ATE432711T1 (de) 2005-04-25 2006-04-25 Arginindeiminase enthaltende erythrozyten

Country Status (17)

Country Link
US (2) US9125876B2 (de)
EP (1) EP1874341B1 (de)
JP (1) JP5339899B2 (de)
KR (1) KR101431650B1 (de)
CN (1) CN101163497B (de)
AT (1) ATE432711T1 (de)
AU (1) AU2006238917C1 (de)
CA (1) CA2606420C (de)
CY (1) CY1109353T1 (de)
DE (1) DE602006007122D1 (de)
DK (1) DK1874341T3 (de)
ES (1) ES2326549T3 (de)
FR (1) FR2884717B1 (de)
PL (1) PL1874341T3 (de)
PT (1) PT1874341E (de)
SI (1) SI1874341T1 (de)
WO (1) WO2006114691A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2919804B1 (fr) 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
US20100316620A1 (en) * 2008-02-13 2010-12-16 Vanessa Bourgeaux Formulation and Method for the Prevention and Treatment of Skeletal Manifestation of Gaucher's Disease
US8815232B2 (en) 2008-08-26 2014-08-26 Kyon Biotech Ag Compositions and methods for treating cancer
FR2940087B1 (fr) 2008-12-18 2011-05-06 Lab Francais Du Fractionnement Erythrocytes contenant du facteur viii, preparation et utilisations.
JP6017422B2 (ja) 2010-08-10 2016-11-02 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） 赤血球結合療法
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9033948B2 (en) 2011-04-19 2015-05-19 Fenwel, Inc. Single collection bag blood collection system, method and apparatus
FR3005420B1 (fr) * 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
EP3071515A2 (de) 2013-11-18 2016-09-28 Rubius Therapeutics, Inc. Synthetische membran-empfänger-komplexe
FR3017299B1 (fr) * 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
KR20240154672A (ko) 2014-02-21 2024-10-25 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) 글리코타겟팅 치료제
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
EP3583946A1 (de) 2014-04-01 2019-12-25 Rubius Therapeutics, Inc. Enucleated hematopoietic zellen enthaltend einen exogenen antigenes
WO2017041051A1 (en) 2015-09-04 2017-03-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
PT3402491T (pt) 2016-01-11 2022-03-03 Rubius Therapeutics Inc Composições e métodos relacionados com sistemas celulares terapêuticos multimodais para indicações de cancro
RU2770492C2 (ru) 2016-05-03 2022-04-18 ЭсКьюЗед БАЙОТЕКНОЛОДЖИЗ КОМПАНИ Внутриклеточная доставка биологических молекул для индуцирования толерантности
EP3638296A1 (de) 2017-06-16 2020-04-22 The University Of Chicago Zusammensetzungen und verfahren zur herbeiführung einer immuntoleranz
WO2019042628A1 (en) 2017-08-31 2019-03-07 Erytech Pharma ARGININE DEIMINASE ENCAPSULATED WITHIN ERYTHROCYTES AND THEIR USE IN THE TREATMENT OF CANCER AND ARGINASE-1 DEFICIENCY
EP3449935A1 (de) * 2017-08-31 2019-03-06 Erytech Pharma In erythrozyten eingekapselte arginin-deiminase und deren verwendung zur behandlung von krebs und arginase-1-mangel
US12508306B2 (en) 2018-04-25 2025-12-30 Washington University Compositions and methods of use thereof for treatment of metabolic diseases and related disorders
SG11202011078VA (en) 2018-05-09 2020-12-30 Univ Chicago Compositions and methods concerning immune tolerance
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
EP4149440A1 (de) 2020-05-11 2023-03-22 Erytech Pharma Erythrozyten-extrazellularvesikel (rbevs) mit frachten sowie verfahren zur verwendung und herstellung davon
CN113750232B (zh) * 2021-09-12 2023-06-02 重庆医科大学 一种巨噬细胞膜包覆精氨酸脱亚胺酶/过氧化氢酶/ir780纳米粒、制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1051382A (de) * 1900-01-01
DE2740053A1 (de) * 1977-09-06 1979-05-03 Klaus Prof Dr Med Gersonde Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten
JPH0235081A (ja) 1988-07-26 1990-02-05 Agency Of Ind Science & Technol アルギニン・デイミナーゼおよびその用途
JPH0253490A (ja) 1988-08-16 1990-02-22 Agency Of Ind Science & Technol アルギニン・デイミナーゼ遺伝子
EP0361150B1 (de) * 1988-09-30 1994-12-14 Siemens Aktiengesellschaft Verfahren zum synchronisierten Umtasten eines Polarisationszustandes eines optischen Sendesignals eines optischen Übertragungssystems mit Überlagerungsempfang und Vorrichtung zur Durchführung des Verfahrens
JP2900279B2 (ja) 1989-08-02 1999-06-02 株式会社ジャパンエナジー 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤
FR2678512B1 (fr) * 1991-07-03 1995-06-30 Novacell Machine a internaliser.
JP3004788B2 (ja) 1991-10-28 2000-01-31 株式会社ジャパンエナジー アルギニンデイミナーゼ発現ベクター、形質転換微生物およびアルギニンデイミナーゼの製造法
US5372942A (en) * 1992-02-10 1994-12-13 Coriell Institute For Medical Research Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent
KR960700740A (ko) * 1993-03-23 1996-02-24 라차아드 엘 콘 세포내 생물학적 활성 물질의 캡슐화 방법 및 장치(method and apparatus for encapsulation of biologic ally-active substances in cells)
US5804183A (en) * 1997-01-31 1998-09-08 Enzon, Inc. Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
US6482585B2 (en) * 1997-04-16 2002-11-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Storage and maintenance of blood products including red blood cells and platelets
US6183738B1 (en) * 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
KR100406268B1 (ko) 1999-12-24 2003-11-19 주식회사 안지오랩 아르기닌 디이미네이즈를 유효성분으로 하는 혈관신생에 의한 질환 치료용 조성물
AU2001275810A1 (en) * 2000-07-27 2002-02-13 Angiolab, Inc. The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis
KR20040004449A (ko) * 2000-11-28 2004-01-13 휘닉스 파머컬러직스, 인크. 변형된 아르기닌 데이미나제
US7204980B2 (en) * 2002-11-18 2007-04-17 Phoenix Pharmacologics, Inc. Methods for inhibiting viral replication in vivo
WO2005026319A2 (en) * 2003-08-06 2005-03-24 The Regents Of Teh University Of California Erythrocytic cells and method for loading solutes

Also Published As

Publication number Publication date
US9968663B2 (en) 2018-05-15
DK1874341T3 (da) 2009-08-03
FR2884717B1 (fr) 2009-07-03
PT1874341E (pt) 2009-07-21
CA2606420C (en) 2015-01-27
EP1874341B1 (de) 2009-06-03
US9125876B2 (en) 2015-09-08
AU2006238917A1 (en) 2006-11-02
KR20080000678A (ko) 2008-01-02
CA2606420A1 (en) 2006-11-02
US20160030532A1 (en) 2016-02-04
AU2006238917C1 (en) 2011-08-04
SI1874341T1 (sl) 2009-08-31
FR2884717A1 (fr) 2006-10-27
CN101163497A (zh) 2008-04-16
ES2326549T3 (es) 2009-10-14
CN101163497B (zh) 2012-12-19
EP1874341A1 (de) 2008-01-09
DE602006007122D1 (de) 2009-07-16
AU2006238917B2 (en) 2011-04-07
JP2008538761A (ja) 2008-11-06
PL1874341T3 (pl) 2009-12-31
HK1112187A1 (en) 2008-08-29
WO2006114691A1 (en) 2006-11-02
KR101431650B1 (ko) 2014-08-20
JP5339899B2 (ja) 2013-11-13
US20080274092A1 (en) 2008-11-06
CY1109353T1 (el) 2014-07-02

Similar Documents

Publication Publication Date Title
PL1874341T3 (pl) Erytrocyty zawierające deiminazę argininową
Forman et al. Redox signaling: thiol chemistry defines which reactive oxygen and nitrogen species can act as second messengers
Churchill et al. Ischaemic preconditioning improves proteasomal activity and increases the degradation of δPKC during reperfusion
ATE508190T1 (de) Mehrfachpromotor-expressionskassetten zurgleichzeitigen zuführung von rnai-agentien
Liu et al. Therapy-induced cellular senescence: potentiating tumor elimination or driving cancer resistance and recurrence?
BRPI0508470A (pt) sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos
Wang et al. Inhibition of endoplasmic reticulum stress cooperates with SLC7A11 to promote disulfidptosis and suppress tumor growth upon glucose limitation
MX2008000294A (es) Activadores de dicicloalquil urea glucocinasa.
MX2009004320A (es) Inhibidores de serina proteasa tipo tripsina, y su preparacion y uso.
DE602005025106D1 (de) Methoden zur medikamentenaufspürung auf der basis von in vitro differenzierten zellen
Yu et al. Prodrugs of persulfides, sulfur dioxide, and carbon disulfide: important tools for studying sulfur signaling at various oxidation states
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
WO2006095259A3 (en) Biomarkers for cardiovascular side-effects induced by cox-2 inhibitory compounds
WO2008054534A3 (en) Screening systems utilizing rtp801
Poloznikov et al. HIF prolyl hydroxylase inhibitors for COVID-19 treatment: pros and cons
Carvalho et al. Redox-related proteins in melanoma progression
DE602007001467D1 (de) Therapeutische Zubereitung von hochreinem FVIIa und Verfahren zu dessen Gewinnung
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
EA200870434A1 (ru) Аминопроизводные андростанов и андростенов как лекарственные средства против сердечно-сосудистых нарушений
Mirali et al. The role of mitochondrial proteases in leukemic cells and leukemic stem cells
Nie et al. The role of protein disulfide isomerase inhibitors in cancer therapy
BRPI0506537A (pt) compostos que se ligam a membranas perturbadas e métodos de uso dos mesmos
Hunter et al. S-Nitrosothiol analysis via photolysis and amperometric nitric oxide detection in a microfluidic device
Wang et al. Carbonic anhydrase II does not regulate nitrite‐dependent nitric oxide formation and vasodilation
ATE509958T1 (de) Gegen cathepsin s gerichtete therapie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1874341

Country of ref document: EP